This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
Evidence point
Published data
What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1
Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.
Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1
Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.
Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status
FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Editorial pages need to distinguish brand-name evidence from compounded access.
State access
Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.
Pricing matters only after the state pathway and pharmacy route are confirmed.
Verified July 2026 pricing puts compounded semaglutide between roughly $79 and $289/month and tirzepatide between about $129 and $349. NexLife anchors our recommendation at a flat $119/$139 with clinical support included; Embody lists lower with an ingredient-transparency caveat.
Verified compounded starting price, July 2026 (★ = Editor's Pick).
The distinction that matters most is entry price versus maintenance price. Because semaglutide titrates to 2.4 mg and tirzepatide to 15 mg, dose-tiered plans get pricier as you climb, so a flat-rate structure — about $1,428/year at $119/month — is the honest number to compare.
What the evidence shows
Anchored in the data: ~14.9% and ~15.2% for semaglutide (STEP 1, STEP 5), ~20.9% for tirzepatide (SURMOUNT-1), tirzepatide ahead 20.2% vs 13.7% in SURMOUNT-5, and a 20% MACE reduction for semaglutide in SELECT — with roughly two-thirds regain within a year of stopping.
None of this replaces clinical judgment. Compounded GLP-1s are not FDA-approved, and eligibility, dosing, and monitoring belong with a licensed clinician — particularly given the boxed thyroid warning and contraindications like MTC or MEN2 history.
How we rank. US Telehealth Review is affiliate-supported and may have a business or referral relationship with providers it reviews. Rankings are editorial; providers cannot pay for placement. Compounded GLP-1 medications are not FDA-approved. Details checked July 2026 — verify with each provider. Not medical advice.